Calidi Biotherapeutics, Inc. (CLDWW)
2025-06-30 | ||||
|---|---|---|---|---|
| Income tax provision | 4 | |||
| General and administrative | 3,071 | |||
| Research and development | 2,593 | |||
| Total operating expense | 5,664 | |||
| Loss from operations | -5,664 | |||
| Other income (expense), net | -22 | |||
| Interest expense-Related Party | 23 | |||
| Interest expense-Nonrelated Party | 29 | |||
| Grant income | - | |||
| Change in fair value of debt, other liabilities, and derivatives-Related Party | 1 | |||
| Change in fair value of debt, other liabilities, and derivatives-Nonrelated Party | 18 | |||
| Total other income (expenses), net | -93 | |||
| Loss before income taxes | -5,757 | |||
| Net loss | -5,761 | |||
| Net loss attributable to noncontrolling interest | -46 | |||
| Net loss attributable to controlling interest | -5,715 | |||
| Deemed dividend on warrants | - | |||
| Net loss attributable to common stockholders | -5,715 | |||
| Net loss per share, basic | -1.99 | |||
| Net loss per share, diluted | -1.99 | |||
| Weighted average common shares outstanding, basic | 2,877 | |||
| Weighted average common shares outstanding, diluted | 2,877 | |||